AVITA Medical's RECELL Platform Wins Top Surgical Innovation Award at MedTech Breakthrough Awards
PorAinvest
jueves, 5 de junio de 2025, 11:21 am ET1 min de lectura
ASX--
The RECELL platform has been FDA-approved and has treated over 30,000 patients worldwide. The technology requires significantly less donor skin than traditional grafting, thereby reducing donor-site pain and accelerating recovery. This results in fewer procedures, improved functional and aesthetic results, and shorter hospital stays. RECELL GO enhances these clinical benefits by improving procedural consistency and surgical team coordination, making it more suitable for high-volume burn and trauma centers.
"We appreciate this recognition, which highlights RECELL’s advantages in burn and trauma care," said Jim Corbett, Chief Executive Officer of AVITA Medical. "By requiring significantly less donor skin than traditional grafting, RECELL reduces donor-site pain, accelerates healing, and improves patient outcomes. We remain committed to expanding access and advancing care for patients."
The MedTech Breakthrough Awards honor companies and products shaping healthcare's future. The 2025 program drew over 4,500 nominations globally. In addition to this recognition, Dr. Katie Bush, Senior Vice President of Scientific & Medical Affairs of AVITA Medical, was awarded the 2025 Emerald Pinnacle Healthcare Award in the Medical Device category.
References:
[1] https://ir.avitamedical.com/news-releases/news-release-details/avita-medicals-recell-platform-recognized-surgical-innovation
MED--
RCEL--
AVITA Medical's RECELL platform, including RECELL GO, has been awarded "Best New Technology Solution – Surgical" at the 2025 MedTech Breakthrough Awards. The FDA-approved technology has treated over 30,000 patients worldwide, requiring less donor skin, reducing pain and recovery time. RECELL GO enhances procedural consistency and surgical team coordination, supporting adoption in high-volume burn centers.
Valencia, Calif., June 5, 2025 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, has received a significant accolade for its RECELL platform. The RECELL platform, including RECELL GO, has been recognized as the "Best New Technology Solution – Surgical" at the 2025 MedTech Breakthrough Awards. This recognition underscores the platform's innovative approach to treating thermal burn wounds and full-thickness skin defects.The RECELL platform has been FDA-approved and has treated over 30,000 patients worldwide. The technology requires significantly less donor skin than traditional grafting, thereby reducing donor-site pain and accelerating recovery. This results in fewer procedures, improved functional and aesthetic results, and shorter hospital stays. RECELL GO enhances these clinical benefits by improving procedural consistency and surgical team coordination, making it more suitable for high-volume burn and trauma centers.
"We appreciate this recognition, which highlights RECELL’s advantages in burn and trauma care," said Jim Corbett, Chief Executive Officer of AVITA Medical. "By requiring significantly less donor skin than traditional grafting, RECELL reduces donor-site pain, accelerates healing, and improves patient outcomes. We remain committed to expanding access and advancing care for patients."
The MedTech Breakthrough Awards honor companies and products shaping healthcare's future. The 2025 program drew over 4,500 nominations globally. In addition to this recognition, Dr. Katie Bush, Senior Vice President of Scientific & Medical Affairs of AVITA Medical, was awarded the 2025 Emerald Pinnacle Healthcare Award in the Medical Device category.
References:
[1] https://ir.avitamedical.com/news-releases/news-release-details/avita-medicals-recell-platform-recognized-surgical-innovation
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios